News | February 09, 2024
Spriya Lifescience Q3 FY24 PAT jumps 213% at Rs. 29.79 Cr
EBITDA for Q3 FY24 almost tripled to reach Rs. 41.49 crore
EBITDA for Q3 FY24 almost tripled to reach Rs. 41.49 crore
Additionally, an MoU was signed between the Dental Council of India and Quality Council of India for the assessment and rating of undergraduate dental colleges
Revenue from Operations stood at Rs. 2,607 crore, 25% YoY growth. Domestic revenue at Rs. 2,400 crore, 20% YoY growth and export revenue at Rs. 207 crore, 118% YoY growth
Union Ayush Minister with Assam Chief Minister lays foundation stone for Central Research Institute of Yoga & Naturopathy
This Phase III clinical trial is a randomized, double-blind, placebo-controlled, multicenter clinical trial in China to evaluate the safety and efficacy of ASC40
This alliance brings together drug innovation capabilities of Glenmark and Ichnos to develop cutting-edge therapies for the treatment of hematological malignancies and solid tumors
Glenmark will be responsible for further developing, registering, and commercializing Envafolimab in India, Asia Pacific, Middle East and Africa, Russia, CIS, and Latin America
The initiative is a response to the rising incidents of heart attacks and cardiac arrests in the state
He is a former Neurology faculty member at The Johns Hopkins Hospital and an elected Fellow of the Royal College of Physicians, United Kingdom
The company also plans to boost its India presence by adding 1,500 beds in the next 2-3 years
Subscribe To Our Newsletter & Stay Updated
